We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Common Contracts

25 similar Securities Purchase Agreement contracts by X4 Pharmaceuticals, Inc, Fusion Pharmaceuticals Inc., Syros Pharmaceuticals, Inc., others

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • June 24th, 2024 • Entrada Therapeutics, Inc. • Pharmaceutical preparations • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of June 24, 2024, by and between Entrada Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • April 11th, 2024 • Century Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of April 11, 2024 by and among Century Therapeutics, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • February 28th, 2024 • vTv Therapeutics Inc. • Pharmaceutical preparations • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of February 27, 2024, by and among vTv Therapeutics Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • February 22nd, 2024 • Ocular Therapeutix, Inc • Pharmaceutical preparations • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of February 21, 2024 by and among Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • February 15th, 2024 • Prelude Therapeutics Inc • Pharmaceutical preparations • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of December 11, 2023, by and among Prelude Therapeutics Incorporated, a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • January 9th, 2024 • Establishment Labs Holdings Inc. • Orthopedic, prosthetic & surgical appliances & supplies • New York
SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • January 8th, 2024 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of January 8, 2024 by and among Solid Biosciences Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • October 26th, 2023 • Monte Rosa Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of October 26, 2023, by and among Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • October 23rd, 2023 • Celcuity Inc. • Services-medical laboratories • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of October 18, 2023, by and among Celcuity Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • May 22nd, 2023 • Krystal Biotech, Inc. • Biological products, (no disgnostic substances) • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 21, 2023, by and among Krystal Biotech, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • May 16th, 2023 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Delaware

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 15, 2023, by and among X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • May 11th, 2023 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 10, 2023 by and among Fusion Pharmaceuticals Inc., a corporation existing under the Canada Business Corporations Act (the “Company”), and the investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • February 14th, 2023 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of February 13, 2023 by and among Fusion Pharmaceuticals Inc., a corporation existing under the Canada Business Corporations Act (the “Company”), and the investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • December 5th, 2022 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of December 5, 2022 by and among Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • July 1st, 2022 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Delaware

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of June 30, 2022 by and among X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • March 3rd, 2022 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Delaware

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of March 3, 2022 by and among X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). For the avoidance of doubt, to the extent that only one Investor is identified on Exhibit A attached hereto, the term Investors as used herein shall refer only to the Investor identified on Exhibit A attached hereto.

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • November 5th, 2021 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Delaware

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of November 5, 2021 by and among X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). For the avoidance of doubt, to the extent that only one Investor is identified on Exhibit A attached hereto, the term Investors as used herein shall refer only to the Investor identified on Exhibit A attached hereto.

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • March 19th, 2021 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Delaware

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of March 18, 2021 by and among X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • December 7th, 2020 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of December 4, 2020 by and among Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • August 11th, 2020 • TFF Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of August 10, 2020 by and among TFF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors identified on the signature pages attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • June 10th, 2020 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of June 9, 2020 by and among Fulcrum Therapeutics, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

Execution Version SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • May 5th, 2020 • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of April 20, 2017 by and among Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • October 1st, 2019 • Constellation Pharmaceuticals Inc • Pharmaceutical preparations • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of October 1, 2019 by and among Constellation Pharmaceuticals Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • April 21st, 2017 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of April 20, 2017 by and among Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • December 1st, 2014 • Eleven Biotherapeutics, Inc. • Pharmaceutical preparations • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of November 24, 2014 by and among Eleven Biotherapeutics, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).